Fig. 1.

MEK inhibitors reduce MD-MSC and MD-HSC viability. Screen of 6 MEK inhibitors against (A) mouse and (B) human WT and MD-SC lines treated for 48–72 h. Mean viability is plotted with IC₅₀ values (n = 1–3 independent experiments; 8 replicates each).